bluuebunny/crossref_metadata_2025_split huggingface dataset:
Alternatively activated macrophages; a double-edged sword in allergic asthma
Authors: Abdelaziz Mohamed Hamed , Abdelwahab Sayed F. , Wan Jie , Cai Wei , Huixuan Wang , Jianjun Cheng , Kumar Kesavan Dinesh , Vasudevan Aparna , Sadek Ahmed , Su Zhaoliang , Wang Shengjun , Xu Huaxi 
Published: March 2020

AbstractBackgroundMacrophages are heterogenous phagocytic cells with an important role in the innate immunity. They are, also, significant contributors in the adaptive immune system. Macrophages are the most abundant immune cells in the lung during allergic asthma, which is the most common chronic respiratory disease of both adults and children. Macrophages activated by Th1 cells are known as M1 macrophages while those activated by IL-4 and IL-13 are called alternatively activated macrophages (AAM) or M2 cells. AAM are subdivided into four distinct subtypes (M2a, M2b, M2c and M2d), depending on the nature of inducing agent and the expressed markers.BodyIL-4 is the major effector cytokine in both alternative activation of macrophages and pathogenesis of asthma. Thus, the role of M2a macrophages in asthma is a major concern. However, this is controversial. Therefore, further studies are required to improve our knowledge about the role of IL-4-induced macrophages in allergic asthma, through precisive elucidation of the roles of specific M2a proteins in the pathogenesis of asthma. In the current review, we try to illustrate the different functions of M2a macrophages (protective and pathogenic roles) in the pathogenesis of asthma, including explanation of how different M2a proteins and markers act during the pathogenesis of allergic asthma. These include surface markers, enzymes, secreted proteins, chemokines, cytokines, signal transduction proteins and transcription factors.ConclusionsAAM is considered a double-edged sword in allergic asthma. Finally, we recommend further studies that focus on increased selective expression or suppression of protective and pathogenic M2a markers.
Characterization of HIV-1 uncoating in human microglial cell lines
Authors: Ingram Zachary , Taylor Melanie , Okland Glister , Martin Richard , Hulme Amy E. 
Published: March 2020

Abstract
Background
After viral fusion with the cell membrane, the conical capsid of HIV-1 disassembles by a process called uncoating. Previously we have utilized the CsA washout assay, in which TRIM-CypA mediated restriction of viral replication is used to detect the state of the viral capsid, to study the kinetics of HIV-1 uncoating in owl monkey kidney (OMK) and HeLa cells. Here we have extended this analysis to the human microglial cell lines CHME3 and C20 to characterize uncoating in a cell type that is a natural target of HIV infection.

Methods
The CsA washout was used to characterize uncoating of wildtype and capsid mutant viruses in CHME3 and C20 cells. Viral fusion assays and nevirapine addition assays were performed to relate the kinetics of viral fusion and reverse transcription to uncoating.

Results
We found that uncoating initiated within the first hour after viral fusion and was facilitated by reverse transcription in CHME3 and C20 cells. The capsid mutation A92E did not significantly alter uncoating kinetics. Viruses with capsid mutations N74D and E45A decreased the rate of uncoating in CHME3 cells, but did not alter reverse transcription. Interestingly, the second site suppressor capsid mutation R132T was able to rescue the uncoating kinetics of the E45A mutation, despite having a hyperstable capsid.

Conclusions
These results are most similar to previously observed characteristics of uncoating in HeLa cells and support the model in which uncoating is initiated by early steps of reverse transcription in the cytoplasm. A comparison of the uncoating kinetics of CA mutant viruses in OMK and CHME3 cells reveals the importance of cellular factors in the process of uncoating. The E45A/R132T mutant virus specifically suggests that disrupted interactions with cellular factors, rather than capsid stability, is responsible for the delayed uncoating kinetics seen in E45A mutant virus. Future studies aimed at identifying these factors will be important for understanding the process of uncoating and the development of interventions to disrupt this process.
CPAP (Continuous Positive Airway Pressure) is an effective and stable solution for heart sparing radiotherapy of left sided breast cancer
Authors: Allen Aaron M. , Ceder Yasmin Korzets , Shochat Tzippy , Fenig Eyal , Popovtzer Aron , Bragilofsky Dimitry , Alfassy Adi , Allon Helena 
Published: March 2020

Abstract
Purpose
Limiting the heart dose in left sided breast cancer radiotherapy is critical. We sought to study the effect of using CPAP (continuous positive airway pressure) as an aid in reducing heart dose in breast cancer radiotherapy.

Methods
Patients with left sided breast cancer receiving adjuvant radiotherapy were enrolled on a prospective IRB (institutional review board) approved clinical trial utilizing CPAP during radiotherapy. Each patient was simulated and planned with and without CPAP and the best dosimetric results determined the patient’s treatment. Data on the differences in lung and heart volume and position as well as boost cavity position with and without CPAP were analyzed.

Results
Twenty-four women from 10/16 to 10/18 were enrolled. Seven patients were not treated on study; only two of these were due to treatment issues. Median age was 54 years. 70% had breast only radiation and 30% were treated to breast\CW (chest wall) and regional nodes. The median lung volume with CPAP was 60% larger than without CPAP. (1637 vs. 996 cc) p < 0.001. The median heart volume decreased 12% with CPAP. (338 vs. 382 cc) In regards to the DVH, CPAP decreased mean heart dose from 3.02 to 1.6Gy (p = .0075) and V20 of the lungs from 17.1 to 13.8 with CPAP but this was not significant.

Conclusion
CPAP assisted radiotherapy was tolerable and produced superior treatment plans in left sided breast cancer. This method is worthy of further investigation as a method to normal tissue sparing treatment of left sided breast cancer patients.
Persistent dyslipidemia in treatment of lysosomal acid lipase deficiency
Authors: Pritchard Amanda Barone , Strong Alanna , Ficicioglu Can 
Published: March 2020

Abstract
Background
Lysosomal acid lipase deficiency (LALD) is an autosomal recessive inborn error of lipid metabolism characterized by impaired lysosomal hydrolysis and consequent accumulation of cholesteryl esters and triglycerides. The phenotypic spectrum is diverse, ranging from severe, neonatal onset failure to thrive, hepatomegaly, hepatic fibrosis, malabsorption and adrenal insufficiency to childhood-onset hyperlipidemia, hepatomegaly, and hepatic fibrosis. Sebelipase alfa enzyme replacement has been approved by the Food and Drug Administration for use in LALD after demonstrating dramatic improvement in transaminitis and dyslipidemia with initiation of enzyme replacement therapy.

Methods
A chart review was performed on 2 patients with childhood-onset, symptomatic LALD with persistent dyslipidemia despite appropriate enzyme replacement therapy to identify biological pathways and risk factors for incomplete response to therapy.

Results
Two patients with attenuated, symptomatic LALD had resolution of transaminitis on enzyme replacement therapy without concomitant effect on dyslipidemia despite dose escalation and no evidence of antibody response to enzyme.

Conclusion
Enzyme replacement therapy does not universally resolve all complications of LALD. Persistent dyslipidemia remains a clinically significant issue, likely related to the complex metabolic pathways implicated in LALD pathogenesis. We discuss the possible mechanistic basis for this unexpected finding and the implications for curative LALD therapy.
Lived experience and attitudes of people with plantar heel pain: a qualitative exploration
Authors: Cotchett Matthew , Rathleff Michael Skovdal , Dilnot Matthew , Landorf Karl B. , Morrissey Dylan , Barton Christian 
Published: March 2020

AbstractBackgroundPlantar heel pain is a common source of pain and disability. Evidence‐based treatment decisions for people with plantar heel pain should be guided by the best available evidence, expert clinical reasoning, and consider the needs of the patient. Education is a key component of care for any patient and needs to be tailored to the patient and their condition. However, no previous work has identified, far less evaluated, the approaches and content required for optimal education for people with plantar heel pain. The aim of this study was to gather the patients' perspective regarding their lived experience, attitudes and educational needs in order to inform the content and provision of meaningful education delivery approaches.MethodsUsing a qualitative descriptive design, semi‐structured interviews were conducted with participants with a clinical diagnosis of plantar heel pain. A topic guide was utilised that focused on the experience of living with plantar heel pain and attitudes regarding treatment and educational needs. Interviews were audio recorded, transcribed verbatim and analysed using the Framework approach. Each transcription, and the initial findings, were reported back to participants to invite respondent validation.ResultsEighteen people with plantar heel pain were interviewed. Descriptive analysis revealed eight themes including perceptions of plantar heel pain, impact on self, dealing with plantar heel pain, source of information, patient needs, patient unmet needs, advice to others and interest in online education. Participants revealed doubt about the cause, treatment and prognosis of plantar heel pain. They also expressed a desire to have their pain eliminated and education individually tailored to their condition and needs. Respondent validation revealed that the transcripts were accurate, and participants were able to recognise their own experiences in the synthesised themes.ConclusionPlantar heel pain has a negative impact on health‐related quality of life. Participants wanted their pain eliminated and reported that their expectations and needs were frequently unmet. Health professionals have an important role to be responsive to the needs of the patient to improve their knowledge and influence pain and behaviour. Our study informs the content needed to help educate people with plantar heel pain.
Protocol for a randomised trial of early kangaroo mother care compared to standard care on survival of pre-stabilised preterm neonates in The Gambia (eKMC)
Authors: Brotherton Helen , Gai Abdou , Tann Cally J. , Samateh Ahmadou Lamin , Seale Anna C. , Zaman Syed M. A. , Cousens Simon , Roca Anna , Lawn Joy E. 
Published: March 2020

Abstract
Background
Complications of preterm birth cause more than 1 million deaths each year, mostly within the first day after birth (47%) and before full post-natal stabilisation. Kangaroo mother care (KMC), provided as continuous skin-to-skin contact for 18 h per day to fully stabilised neonates ≤ 2000 g, reduces mortality by 36–51% at discharge or term-corrected age compared with incubator care. The mortality effect of starting continuous KMC before stabilisation is a priority evidence gap, which we aim to investigate in the eKMC trial, with a secondary aim of understanding mechanisms, particularly for infection prevention.

Methods
We will conduct a single-site, non-blinded, individually randomised, controlled trial comparing two parallel groups to either early (within 24 h of admission) continuous KMC or standard care on incubator or radiant heater with KMC when clinically stable at > 24 h of admission. Eligible neonates (n = 392) are hospitalised singletons or twins < 2000 g and 1–24 h old at screening who are mild to moderately unstable as per a trial definition using cardio-respiratory parameters. Randomisation is stratified by weight category (< 1200 g; ≥ 1200 g) and in random permuted blocks of varying sizes with allocation of twins to the same arm. Participants are followed up to 28 ± 5 days of age with regular inpatient assessments plus criteria-led review in the event of clinical deterioration. The primary outcome is all-cause neonatal mortality by age 28 days. Secondary outcomes include the time to death, cardio-respiratory stability, hypothermia, exclusive breastfeeding at discharge, weight gain at age 28 days, clinically suspected infection (age 3 to 28 days), intestinal carriage of extended-spectrum beta-lactamase producing (ESBL) Klebsiella pneumoniae (age 28 days), and duration of the hospital stay. Intention-to-treat analysis will be applied for all outcomes, adjusting for twin gestation.

Discussion
This is one of the first clinical trials to examine the KMC mortality effect in a pre-stabilised preterm population. Our findings will contribute to the global evidence base in addition to providing insights into the infection prevention mechanisms and safety of using this established intervention for the most vulnerable neonatal population.

Trial registration
ClinicalTrials.gov NCT03555981. Submitted 8 May 2018 and registered 14 June 2018. Prospectively registered.
Protein A/G-based enzyme-linked immunosorbent assay for detection of anti-Pythium insidiosum antibodies in human and animal subjects
Authors: Jaturapaktrarak Chalisa , Payattikul Penpan , Lohnoo Tassanee , Kumsang Yothin , Laikul Aree , Pathomsakulwong Watcharapol , Yurayart Chompoonek , Tonpitak Walaiporn , Krajaejun Theerapong 
Published: March 2020

Abstract
Objectives
Pythiosis is a deadly infectious disease caused by Pythium insidiosum. Reports of both human and animal pythiosis are on the rise worldwide. Prognosis of the pythiosis patients relies on early diagnosis and prompt treatment. There are needs for an immunodiagnostic test that can detect the disease in both humans and animals. This study aims at reporting an optimized protocol for the development of a protein A/G-based enzyme-linked immunosorbent assay (ELISA) for the detection of anti-P. insidiosum antibody in multiple host species.

Results
A total of 25 pythiosis and 50 control sera, obtained from humans, horses, dogs, cats, and cows, were recruited for the assay development. With a proper ELISA cutoff point, all pythiosis sera can ultimately be distinguished from the control sera. The successfully-developed protein A/G-based ELISA can detect the anti-P. insidiosum antibodies in serum samples of both humans and animals. It is a versatile, feasible-to-develop, and functional immunodiagnostic assay for pythiosis.
Null controllability of a semilinear degenerate parabolic equation with a gradient term
Authors: Xu Fengdan , Zhou Qian , Nie Yuanyuan 
Published: March 2020

AbstractThis paper concerns the null controllability of a semilinear control system governed by degenerate parabolic equation with a gradient term, where the nonlinearity of the problem is involved with the first derivative. We first establish the well-posedness and prove the approximate null controllability of the linearized system, then we can get the approximate null controllability of the semilinear control system by a fixed point argument. Finally, the semilinear control system with a gradient term is shown to be null controllable.
Certain properties of difference operator and stability of Fréchet functional equation
Authors: Sukhonwimolmal Teerapol 
Published: March 2020

AbstractLet M be a commutative monoid, and let B be a Banach space. We give a new recursive method to obtain a Gǎvruţa-type stability result for the functional equation Δyn+1f(x):=∑k=0n+1(−1)n+1+k(n+1k)f(x+ky)=0 via algebraic manipulations of the forward difference operator.
A cohort study of quality of life in partners of young breast cancer survivors compared to partners of healthy controls
Authors: Cohee Andrea , Storey Susan , Winger Joseph G. , Cella David , Stump Timothy , Monahan Patrick O. , Champion Victoria L. 
Published: March 2020

Abstract
Background
Partners of young breast cancer survivors (BCS) are at increased risk for deficits in quality of life (QoL). To intervene effectively, it is important to understand how the breast cancer experience impacts partners. The purpose of this study was to compare QoL between partners of young BCS and partners of healthy acquaintance controls.

Methods
Partners of young BCS (3–8 years post treatment and ≤ 45 years old at diagnosis) and partners of age-matched healthy acquaintance controls completed questionnaires on overall, physical (physical function, sexual difficulty), social (personal resources, sexual enjoyment, marital satisfaction, partner social support, social constraints, parenting satisfaction), psychological (depressive symptoms), and spiritual (behaviors, beliefs, and activities) QoL. Analyses included descriptive statistics and one-way ANOVA to compare partner groups on all study variables.

Results
Although partners of young BCS (n = 227) reported fewer social constraints (p < .001), they reported lower overall QoL (p < .001), fewer personal resources (p < .001), more sexual difficulty (p = .019), less sexual enjoyment (p = .002), less marital satisfaction (p = .019), more depressive symptoms (p = .024), and fewer spiritual behaviors (p < .001), beliefs (p = .001) and activities (p = .003) compared to partners of healthy acquaintance controls (n = 170). Additional analysis showed that perceptions that the relationship changed for the better since cancer, social constraints, partner social support, and depression predicted marital satisfaction among partners of young BCS.

Conclusions
Partners of young BCS are at risk for poorer overall, physical, social, psychological, and spiritual QoL compared to partners of healthy women. Interventions targeting QoL domains may enable partners to effectively support their partner and improve their QoL.
Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study
Authors: Yan Adam P. , Chen Yan , Henderson Tara O. , Oeffinger Kevin C. , Hudson Melissa M. , Gibson Todd M. , Neglia Joseph P. , Leisenring Wendy M. , Ness Kirsten K. , Ford Jennifer S. , Robison Leslie L. , Armstrong Gregory T. , Yasui Yutaka , Nathan Paul C. 
Published: March 2020

PURPOSE To evaluate childhood cancer survivors’ adherence to surveillance protocols for late effects of treatment and to determine the factors affecting adherence. METHODS Between 2014 and 2016, 11,337 survivors and 2,146 siblings in the Childhood Cancer Survivor Study completed a survey ascertaining adherence to Children’s Oncology Group (COG) guidelines for survivors at high risk for second malignant neoplasms or cardiac dysfunction and to the American Cancer Society (ACS) cancer screening guidelines for average-risk populations. Adherence rates and factors affecting adherence were analyzed. RESULTS Median age at diagnosis was 7 years (range, 0-20.9 years), and median time from diagnosis was 29 years (range, 15-47 years). Among high-risk survivors, adherence to COG breast, colorectal, skin, and cardiac surveillance was 12.6% (95% CI, 10.0% to 15.3%), 37.0% (34.1% to 39.9%), 22.3% (21.2% to 23.4%), and 41.4% (40.1% to 42.7%), respectively. Among average-risk survivors, adherence to ACS breast, cervical, and colorectal screening was 57.1% (53.2% to 61.0%), 83.6% (82.7% to 84.5%), and 68.5% (64.7% to 72.2%), respectively. Twenty-seven percent of survivors and 20.0% of primary care providers (PCPs) had a survivorship care plan (SCP). For high-risk survivors, SCP possession was associated with increased adherence to COG breast (22.3% v. 8.1%; prevalence ratio [PR], 2.52; CI, 1.59 to 4.01), skin (34.8% v 23.0%; PR, 1.16; CI, 1.01 to 1.33), and cardiac (67.0% v 33.1%; PR, 1.73; CI, 1.55 to 1.92) surveillance. For high-risk survivors, PCP possession of a SCP was associated only with increased adherence to COG skin cancer surveillance (36.9% v 23.2%; PR, 1.24; CI, 1.08 to 1.43). CONCLUSION Guideline adherence is suboptimal. Although survivor SCP possession is associated with better adherence, few survivors and PCPs have one. New strategies to improve adherence are needed.
High expression of the chemokine receptor CXCR4 is associated with estrogen receptor-negative breast cancer
Authors: Wheler J. J. , Doane A. S. , Linkov I. , Hudis C. A. , Gerald W. 
Published: March 2020

642 Background: Chemokine receptor CXCR4 and its ligand CXCL12 (SDF-1alpha) are important in the metastatic spread of breast cancer. Previous studies have shown that CXCR4 is overexpressed in breast cancers as compared to normal breast tissue and that estradiol increases levels of CXCL12. The association between CXCR4 and estrogen receptor (ER) status is unclear. Methods: We performed genome-wide molecular analysis of 61 primary breast cancer tissue samples. Total RNA was extracted and hybridized to Affymetrix HG-U133 oligonucleotide microarrays, and differentially expressed genes between groups were identified using a Welch t-test. CXCR4 protein expression was evaluated by immunohistochemistry (IHC) using a monoclonal antibody (R&D Systems, Minneapolis, MN). We characterized CXCR4 nuclear staining as high vs low-medium. Several clinico-pathologic variables were correlated with CXCR4 expression. Results: A predominantly nuclear staining pattern was noted for CXCR4. Of 61 primary tumors, 15 had high nuclear expression and 46 had low-medium expression. High levels of nuclear CXCR4 expression were significantly correlated with ER-negativity (p =0.0005). CXCR4 protein expression had no association with Her-2 status (gene copy number or IHC 3+), tumor size, or lymph node status. Using p<0.001, protein expression of CXCR4 was associated with 105 significantly differentially expressed genes including relative under expression of ER and ER-related genes and over expression of VEGF. Conclusion: High nuclear protein expression levels of CXCR4 in primary breast cancers are significantly associated with ER-negativity and with low differential expression of ER and ER-related genes. Since estrogen may play a role in CXCR4 activation, further investigation of the association of high CXCR4 expression and ER-negativity is planned. No significant financial relationships to disclose.